Viatris And FKB Introduce First Japanese Adalimumab Biosimilar
Rival To Humira Launched Following Approval Last June
Executive Summary
Viatris and Fujifilm Kyowa Kirin Biologics have introduced Japan’s first biosimilar rival to Humira.
You may also be interested in...
AbbVie Sees Solid Japan Outlook Despite 2020 Dip
AbbVie expects double-digit sales growth in Japan over the mid-term despite a decline last year, driven in large part by multi-indication plans for new products.
Viatris Expects First Interchangeable Biosimilar Designations For Insulins In July
Amid continued debate over biosimilar interchangeability in the US, Viatris has said it expects to pick up the first such approvals later this year with the company’s insulin glargine and insulin aspart biosimilar products.
Five Competitors Confirmed On Canadian Adalimumab
Multiple competitors have now confirmed the launch of Canadian biosimilar versions of the world’s biggest-selling drug, Humira.